Grünenthal Pharma Ltd are pleased to announce the completion of the transfer of the Marketing Authorization for Nexium (esomeprazole magnesium trihydrate) to Grünenthal Pharma Ltd on March 20th 2020.
The transfer is part of a US$ 922m deal between AstraZeneca and Grünenthal whereby Grünenthal acquired the European rights to Nexium and the global (ex US and Japan) rights to Vimovo (naproxen 500mg /esomeprazole 20mg).
For verified healthcare professionals
Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.
